Coenzyme Q10 and statin-related myopathy.
Level 5 - mechanism / opinion, no new human data
Narrative review/commentary without new empirical data or systematic synthesis
PubMed 25977402 · doi:10.1136/dtb.2015.5.0325
What was done
This narrative article examined the biochemical mechanisms linking statin therapy, endogenous coenzyme Q10 depletion, and muscle-related adverse effects, and considered whether coenzyme Q10 supplementation has a role in managing statin-induced myopathy.
What was found
The abstract reports no numerical findings, effect sizes, or study outcomes. It describes the biological rationale that statins reduce coenzyme Q10 synthesis via HMG-CoA reductase inhibition and discusses whether supplementation alleviates statin-induced myopathy.
Why it matters
Statin-associated muscle symptoms are a common clinical challenge, making clarification of the evidence surrounding coenzyme Q10 supplementation clinically relevant.
Limits
The abstract reports no primary clinical data, quantitative statistics, or systematic review methodology. Sample size, study selection criteria, and specific trial outcomes are not described.
Cited by
- supports The mevalonate pathway that synthesizes cholesterol also produces coenzyme Q10.